Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2024

Open Access 18-01-2024 | Urinary Tract Infection | Original Article

Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study

Authors: Joachim Doua, Miquel Ekkelenkamp, Theo Verheij, Oscar Go, Stephen Ruhmel, Kimberly Leathers, Bart Spiessens, Sanne van Rooij, Vance G. Fowler Jr., Jeroen Geurtsen, Rowena Dolor, Michal Sarnecki, Ranee Chatterjee, Jan Poolman, Marc Bonten, on behalf COMBACTE-NET consortium/EXPECT study group

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2024

Login to get access

Abstract

Purpose

Invasive Escherichia coli disease (IED) encompasses a diverse range of sterile site infections. This study evaluated the feasibility of capturing IED among community-dwelling older adults to inform the implementation of a phase 3 efficacy trial of a novel vaccine against IED (NCT04899336).

Methods

EXPECT-1 (NCT04087681) was a prospective, multinational, observational study conducted in medically stable participants aged ≥ 60 years. At least 50% of participants were selected based on a history of urinary tract infection (UTI) in the previous 10 years. The main outcomes were the incidence of IED and the number of hospitalisations reported by the site vs participant. The length of follow-up was 12 months. In a US-based substudy, a smartphone-based geofencing was evaluated to track hospital entries.

Results

In total, 4470 participants were enrolled (median age, 70.0 years); 59.5% (2657/4469) of participants had a history of UTI in the previous 10 years. Four IED events were captured through deployment of different tracking methods: a self-report, a general practitioner (GP) report, and a follow-up call. The incidence rate of IED was 98.6 events per 100,000 person-years. The number of reported hospitalisations was 2529/4470 (56.6%) by the site and 2177/4470 (48.7%) by participants; 13.8% of hospitalisations would have been missed if utilising only site reports. Geofencing detected 72 hospital entries.

Conclusion

Deployment of multiple tracking methods can optimise detection of IED among community-dwelling older adults. Older adults with a history of UTI could be feasibly targeted for a phase 3 vaccine efficacy trial through a network of GPs.
Appendix
Available only for authorised users
Literature
4.
go back to reference Fay K, Sapiano MRP, Gokhale R, Dantes R, Thompson N, Katz DE, Ray SM, Wilson LE, Perlmutter R, Nadle J, Godine D, Frank L, Brousseau G, Johnston H, Bamberg W, Dumyati G, Nelson D, Lynfield R, DeSilva M, Kainer M, Zhang A, Ocampo V, Samper M, Pierce R, Irizarry L, Sievers M, Maloney M, Fiore A, Magill SS, Epstein L (2020) Assessment of health care exposures and outcomes in adult patients with sepsis and septic shock. JAMA Netw Open 3:e206004. https://doi.org/10.1001/jamanetworkopen.2020.6004CrossRefPubMedPubMedCentral Fay K, Sapiano MRP, Gokhale R, Dantes R, Thompson N, Katz DE, Ray SM, Wilson LE, Perlmutter R, Nadle J, Godine D, Frank L, Brousseau G, Johnston H, Bamberg W, Dumyati G, Nelson D, Lynfield R, DeSilva M, Kainer M, Zhang A, Ocampo V, Samper M, Pierce R, Irizarry L, Sievers M, Maloney M, Fiore A, Magill SS, Epstein L (2020) Assessment of health care exposures and outcomes in adult patients with sepsis and septic shock. JAMA Netw Open 3:e206004. https://​doi.​org/​10.​1001/​jamanetworkopen.​2020.​6004CrossRefPubMedPubMedCentral
9.
go back to reference A study of vaccination with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) in the prevention of invasive extraintestinal pathogenic Escherichia coli disease in adults aged 60 years and older with a history of urinary tract infection in the past 2 years. NCT04899336. https://clinicaltrials.gov/study/NCT04899336. Accessed 17 Jan 2024 A study of vaccination with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) in the prevention of invasive extraintestinal pathogenic Escherichia coli disease in adults aged 60 years and older with a history of urinary tract infection in the past 2 years. NCT04899336. https://​clinicaltrials.​gov/​study/​NCT04899336. Accessed 17 Jan 2024
Metadata
Title
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study
Authors
Joachim Doua
Miquel Ekkelenkamp
Theo Verheij
Oscar Go
Stephen Ruhmel
Kimberly Leathers
Bart Spiessens
Sanne van Rooij
Vance G. Fowler Jr.
Jeroen Geurtsen
Rowena Dolor
Michal Sarnecki
Ranee Chatterjee
Jan Poolman
Marc Bonten
on behalf COMBACTE-NET consortium/EXPECT study group
Publication date
18-01-2024
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2024
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-023-04738-y

Other articles of this Issue 3/2024

European Journal of Clinical Microbiology & Infectious Diseases 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.